Loading
1 standard-of-care settings across 1 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers |
|---|---|
| Other settings | 1 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | All cases | Maximal safe resection and proton radiotherapy as on the chordoma page; EZH2 inhibition is under study for SMARCB1-deficient tumours, but the first EZH2 inhibitor, tazemetostat, was withdrawn worldwide in 2026 after secondary blood cancers, so the class is being re-examined rather than used. | 32 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.